Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver.

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn, with market analysis describing the deal as a “bargain”.

Eli Lilly (NYSE:LLY) is reportedly nearing a deal to acquire gene editing startup Verve Therapeutics (NASDAQ:VERV) for up to $1.3B, the Financial Times reported. The drugmaker's acquisition offer ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies.

Eli Lilly to buy Verve Therapeutics for $10.50 per share, with total potential payout up to $13.50 per share. The $1.3 billion deal offers a 113% premium to Verve’s 30-day average stock price.

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. The deal centers on an exciting cardiovascular health ...

INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV).

(RTTNews) - Eli Lilly and Co. (LLY) announced Friday the successful completion of its acquisition of Verve Therapeutics, Inc. (VERV). Verve is a Boston-based clinical-stage company developing ...

Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion. A woman in a lab coat examining a syringe of gene editing medicine in a laboratory setting.

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk By Eli Lilly and Company, Verve Therapeutics, Inc. Jun 17, 2025 Updated Jun 17, 2025 1 of 2 ...